Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill shows promise against tough cancers in early trial

NCT ID NCT04045496

First seen Dec 29, 2025 · Last updated May 21, 2026 · Updated 15 times

Summary

This early-phase study tested a new daily pill called JAB-3312 in 40 adults with advanced solid tumors (like lung, colorectal, or breast cancer) that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors, but this is a first step to see if the drug is safe enough for larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • HealthONE Clinic Services Oncology-Hematology

    Denver, Colorado, 80202, United States

  • Tennessee Oncology, PLLC

    Nashville, Tennessee, 37203, United States

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Washington University School of Medicine

    Seattle, Washington, 63110, United States

Conditions

Explore the condition pages connected to this study.